Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Thiamine deficiency in a patient with recurrent renal cell carcinoma who developed weight loss with normal appetite and loss of energy soon after nivolumab treatment.

Onishi H, Okabe T, Uchida N, Shirotake S, Todo M, Oyama M, Ishida M.

Palliat Support Care. 2019 Sep 19:1-3. doi: 10.1017/S1478951519000658. [Epub ahead of print]

PMID:
31535612
2.

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Shirotake S, Takamatsu K, Mizuno R, Kaneko GO, Nishimoto K, Oya M, Oyama M.

Anticancer Res. 2019 Aug;39(8):4371-4377. doi: 10.21873/anticanres.13606.

PMID:
31366532
3.

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy.

Kaneko G, Shirotake S, Nishimoto K, Miyazaki Y, Ito K, Ito Y, Hagiwara M, Kanao K, Nakagawa K, Momma T, Asano T, Tanaka N, Mizuno R, Oya M, Oyama M.

Jpn J Clin Oncol. 2019 Aug 1;49(8):780-785. doi: 10.1093/jjco/hyz067.

PMID:
31063191
4.

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature.

Umezawa Y, Shirotake S, Kaneko G, Nishimoto K, Okada Y, Uchino A, Yasuda M, Oyama M.

Mol Clin Oncol. 2019 May;10(5):506-510. doi: 10.3892/mco.2019.1820. Epub 2019 Mar 5.

5.

Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib.

Todo M, Shirotake S, Nishimoto K, Yasumizu Y, Kaneko G, Kondo H, Okabe T, Makabe H, Oyama M.

Anticancer Res. 2019 Feb;39(2):999-1004. doi: 10.21873/anticanres.13205.

PMID:
30711987
6.

Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report.

Shirotake S, Kaneko G, Nagata K, Oyama M, Nishimoto K.

Mol Clin Oncol. 2019 Feb;10(2):244-248. doi: 10.3892/mco.2018.1779. Epub 2018 Nov 28.

7.

Early tumor shrinkage as a predictive factor of metastatic renal cell carcinoma in molecular targeted therapy: A single institutional study.

Shirotake S, Kondo H, Okabe T, Makino S, Araki R, Komatsuda A, Kaneko G, Nishimoto K, Oyama M.

Mol Clin Oncol. 2019 Jan;10(1):125-131. doi: 10.3892/mco.2018.1762. Epub 2018 Nov 12.

8.

Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study.

Shirotake S, Makino S, Suzuki K, Araki R, Kosaka T, Nishimoto K, Oyama M, Kato S.

Jpn J Clin Oncol. 2019 Jan 1;49(1):87-91. doi: 10.1093/jjco/hyy174.

PMID:
30476164
9.

A Case of Renal Oncocytoma with Renal Venous Tumor Thrombus.

Kondo H, Okabe T, Okada Y, Hasebe T, Shirotake S, Oyama M, Nishimoto K.

Keio J Med. 2019 Jun 25;68(2):39-41. doi: 10.2302/kjm.2017-0012-CR. Epub 2018 Nov 23.

10.

Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.

Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Momma T, Masuda T, Nakagawa K, Oyama M, Asano T, Oya M.

Jpn J Clin Oncol. 2019 Jan 1;49(1):69-76. doi: 10.1093/jjco/hyy154.

PMID:
30407543
11.

Clinical Impact of Consolidative and Salvage Radiotherapy for Lymph Node Metastasis in Upper Urinary Tract Urothelial Carcinoma.

Kondo H, Shirotake S, Okabe T, Makino S, Nishimoto K, Oyama M.

Case Rep Urol. 2018 Apr 22;2018:1471839. doi: 10.1155/2018/1471839. eCollection 2018.

12.

History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.

Kayama E, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, Hakozaki K, Kaneko G, Yoshimine S, Tanaka N, Takahiro M, Kanai K, Oyama M, Nakajima Y, Hara S, Monma T, Oya M.

Clin Genitourin Cancer. 2018 Oct;16(5):e969-e976. doi: 10.1016/j.clgc.2018.04.004. Epub 2018 Apr 28.

PMID:
29778322
13.

Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls.

Yano A, Arai Y, Kitayama S, Otsuka Y, Shirotake S, Kawakami S.

Int J Urol. 2018 Aug;25(8):758-759. doi: 10.1111/iju.13703. Epub 2018 May 14. No abstract available.

14.
15.

Embolization Using N-butyl Cyanoacrylate for Postoperative Lymphatic Leakage: A Case Report.

Kayama E, Nishimoto K, Kaneko G, Shirotake S, Hayashi T, Kondo H, Okabe T, Nakazawa K, Oyama M.

Clin Genitourin Cancer. 2018 Apr;16(2):e355-e371. doi: 10.1016/j.clgc.2017.12.011. Epub 2017 Dec 29. No abstract available.

16.

Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy.

Hakozaki K, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, Maeda T, Kaneko G, Yoshimine S, Tanaka N, Kanai K, Oyama M, Nakajima Y, Momma T, Oya M.

Med Oncol. 2017 Oct 23;34(12):187. doi: 10.1007/s12032-017-1048-5.

PMID:
29063301
17.

Editorial Comment to Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.

Shirotake S, Nishimoto K.

Int J Urol. 2017 Nov;24(11):785-786. doi: 10.1111/iju.13437. Epub 2017 Sep 14. No abstract available.

18.

External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.

Tanaka N, Mizuno R, Ito K, Shirotake S, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.

Eur Urol Focus. 2016 Aug;2(3):303-309. doi: 10.1016/j.euf.2015.11.001. Epub 2015 Dec 2.

PMID:
28723377
19.

Determining the optimum way to maintain quality of life for very elderly patients with advanced bladder cancer and poor performance status: A case report.

Suzuki K, Hanashima F, Shirotake S, Kodaira K, Nishimoto K, Takahashi T, Onishi H, Oyama M.

Mol Clin Oncol. 2017 Jun;6(6):968-970. doi: 10.3892/mco.2017.1236. Epub 2017 May 5.

20.

Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.

Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M.

Eur J Hybrid Imaging. 2017;1(1):2. doi: 10.1186/s41824-017-0006-y. Epub 2017 Oct 12.

21.

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.

Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.

Urol Oncol. 2017 Feb;35(2):39.e19-39.e28. doi: 10.1016/j.urolonc.2016.10.001. Epub 2016 Nov 4.

PMID:
27825515
22.

Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.

Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M.

Clin Genitourin Cancer. 2016 Dec;14(6):e575-e583. doi: 10.1016/j.clgc.2016.03.014. Epub 2016 Mar 24.

PMID:
27102405
23.

Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.

Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.

Urol Oncol. 2016 Jul;34(7):293.e17-25. doi: 10.1016/j.urolonc.2016.02.023. Epub 2016 Apr 1.

PMID:
27040380
24.

Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy.

Kobayashi H, Kikuchi E, Tanaka N, Shirotake S, Miyazaki Y, Ide H, Obata J, Hoshino K, Matsumoto K, Kaneko G, Hagiwara M, Kosaka T, Oyama M, Nakajima Y, Oya M.

Jpn J Clin Oncol. 2016 Jun;46(6):554-559. doi: 10.1093/jjco/hyw028. Epub 2016 Mar 9.

PMID:
26962241
25.

Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M.

Eur Urol Focus. 2015 Aug;1(1):54-63. doi: 10.1016/j.euf.2015.02.001. Epub 2015 May 23.

26.

Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery.

Miyajima A, Yazawa S, Kosaka T, Tanaka N, Shirotake S, Mizuno R, Kikuchi E, Oya M.

Ann Surg Oncol. 2015 Oct;22(11):3751-9. doi: 10.1245/s10434-015-4436-0. Epub 2015 Feb 18.

PMID:
25691280
27.

Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.

Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M.

J Urol. 2015 Apr;193(4):1122-8. doi: 10.1016/j.juro.2014.10.022. Epub 2014 Oct 13.

PMID:
25444957
28.

The impact of HIF1α on the Per2 circadian rhythm in renal cancer cell lines.

Okabe T, Kumagai M, Nakajima Y, Shirotake S, Kodaira K, Oyama M, Ueno M, Ikeda M.

PLoS One. 2014 Oct 21;9(10):e109693. doi: 10.1371/journal.pone.0109693. eCollection 2014.

29.

A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Oyama M, Momma T, Nakajima Y, Jinzaki M, Oya M.

Ann Surg Oncol. 2014 Nov;21(12):4041-8. doi: 10.1245/s10434-014-3830-3. Epub 2014 Jun 10.

PMID:
24912614
30.

Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Hagiwara M, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Hasegawa S, Nakajima Y, Oya M.

Ann Surg Oncol. 2014 Sep;21(9):3151-8. doi: 10.1245/s10434-014-3657-y. Epub 2014 Mar 29.

PMID:
24682698
31.

Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H, Miyazaki Y, Obata J, Hoshino K, Shirotake S, Akita H, Kosaka T, Miyajima A, Momma T, Nakagawa K, Hasegawa S, Nakajima Y, Jinzaki M, Oya M.

Ann Surg Oncol. 2014 Mar;21(3):1038-45. doi: 10.1245/s10434-013-3349-z. Epub 2013 Nov 12.

PMID:
24217788
32.

The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Nakajima Y, Oya M.

Urol Oncol. 2014 Jan;32(1):48.e19-26. doi: 10.1016/j.urolonc.2013.07.003. Epub 2013 Sep 18.

PMID:
24055429
33.

Construction of a three-dimensional model of cardiovascular disease and deployment of a new method of fostering patient adherence to instruction.

Nakano M, Shirotake S.

Patient Prefer Adherence. 2013 Jun 25;7:579-87. doi: 10.2147/PPA.S45012. Print 2013.

34.

Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Shirotake S, Hayakawa N, Kosaka T, Miyajima A, Momma T, Nakagawa K, Hasegawa S, Nakajima Y, Oya M.

BJU Int. 2013 Jul;112(2):E28-34. doi: 10.1111/bju.12133.

35.

Bacteriolysis by vancomycin-conjugated acryl nanoparticles and morphological component analysis.

Shimizu N, Otsuka K, Sawada H, Maejima T, Shirotake S.

Drug Dev Ind Pharm. 2014 Jun;40(6):813-8. doi: 10.3109/03639045.2013.788012. Epub 2013 Apr 17.

PMID:
23594303
36.

The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.

Tanaka N, Kikuchi E, Shirotake S, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Ito Y, Kosaka T, Kodaira K, Oyama M, Miyajima A, Momma T, Nakagawa K, Ueno M, Oya M.

Eur Urol. 2014 Jan;65(1):227-34. doi: 10.1016/j.eururo.2012.11.050. Epub 2012 Dec 1.

PMID:
23219372
37.

Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer.

Yuge K, Miyajima A, Tanaka N, Shirotake S, Kosaka T, Kikuchi E, Oya M.

Ann Surg Oncol. 2012 Nov;19(12):3987-93. doi: 10.1245/s10434-012-2568-z. Epub 2012 Aug 8.

PMID:
22872290
38.

Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.

Shirotake S, Miyajima A, Kosaka T, Tanaka N, Kikuchi E, Mikami S, Okada Y, Oya M.

Am J Pathol. 2012 Mar;180(3):1008-16. doi: 10.1016/j.ajpath.2011.11.027. Epub 2012 Jan 6.

PMID:
22226738
39.

Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer.

Tanaka N, Miyajima A, Kosaka T, Miyazaki Y, Shirotake S, Shirakawa H, Kikuchi E, Oya M.

Br J Cancer. 2011 Oct 25;105(9):1331-7. doi: 10.1038/bjc.2011.399. Epub 2011 Oct 4.

40.

A case of angiomyolipoma of the renal sinus.

Shirotake S, Yoshimura I, Kosaka T, Matsuzaki S.

Clin Exp Nephrol. 2011 Dec;15(6):953-6. doi: 10.1007/s10157-011-0519-9. Epub 2011 Aug 17.

PMID:
21847520
41.

Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.

Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M.

J Urol. 2011 Jun;185(6):2376-81. doi: 10.1016/j.juro.2011.02.016. Epub 2011 Apr 20.

PMID:
21511293
42.

Effect of anionic and cationic n-butylcyanoacrylate nanoparticles on NO and cytokine production in Raw264.7 cells.

Tomita Y, Rikimaru-Kaneko A, Hashiguchi K, Shirotake S.

Immunopharmacol Immunotoxicol. 2011 Dec;33(4):730-7. doi: 10.3109/08923973.2011.565345. Epub 2011 Apr 4.

PMID:
21457109
43.

Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.

Hasegawa M, Miyajima A, Kosaka T, Yasumizu Y, Tanaka N, Maeda T, Shirotake S, Ide H, Kikuchi E, Oya M.

Int J Cancer. 2012 Jan 15;130(2):431-42. doi: 10.1002/ijc.26012. Epub 2011 Apr 25.

44.

Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.

Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Oya M.

Prostate. 2011 Oct 1;71(14):1510-7. doi: 10.1002/pros.21367. Epub 2011 Feb 14.

PMID:
21321983
45.

Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer.

Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, Oya M.

Urology. 2011 Apr;77(4):1009.e19-25. doi: 10.1016/j.urology.2010.11.002. Epub 2011 Feb 5.

PMID:
21296393
46.

[Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma].

Yoshii T, Horiguchi A, Shirotake S, Tobe M, Hayakawa M, Sumitomo M, Asano T.

Hinyokika Kiyo. 2010 Nov;56(11):639-43. Japanese.

47.

Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer.

Tanaka N, Miyajima A, Kosaka T, Shirotake S, Hasegawa M, Kikuchi E, Oya M.

Mol Cancer Ther. 2010 Nov;9(11):2982-92. doi: 10.1158/1535-7163.MCT-10-0535. Epub 2010 Oct 26.

48.

[Case of primary amelanotic malignant melanoma of the female urethra].

Yoshii T, Horiguchi A, Shirotake S, Tobe M, Tasaki S, Hayakawa M, Sumitomo M, Asano T.

Nihon Hinyokika Gakkai Zasshi. 2010 Sep;101(6):734-7. Japanese.

PMID:
20954381
49.

Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion.

Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M, Okada Y, Oya M.

Clin Cancer Res. 2010 Dec 1;16(23):5814-23. doi: 10.1158/1078-0432.CCR-10-0230. Epub 2010 Oct 14.

50.

[Urothelial carcinoma clear cell variant of the urinary bladder : a case report].

Isono M, Asano T, Shirotake S, Tasaki S, Asakuma J, Satoh M, Kimura F, Dai Y, Aida S.

Hinyokika Kiyo. 2010 Mar;56(3):163-5. Review. Japanese.

Supplemental Content

Loading ...
Support Center